scispace - formally typeset
Open AccessJournal ArticleDOI

Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes.

Reads0
Chats0
TLDR
The median cytotoxicity of the test compounds increased between 1 and 2 days of incubation, with no or only a minimal further increase until day 7, and it remains to be studied whether the different results obtained for some individual compounds after longer exposure periods would correspond better to human-repeated dose toxicity.
Abstract
Primary human hepatocytes (PHHs) remain the gold standard for in vitro testing in the field of pharmacology and toxicology. One crucial parameter influencing the results of in vitro tests is the incubation period with test compounds. It has been suggested that longer incubation periods may be critical for the prediction of repeated dose toxicity. However, a study that systematically analyzes the relationship between incubation period and cytotoxicity in PHHs is not available. To close this gap, 30 compounds were tested in a concentration-dependent manner for cytotoxicity in cultivated cryopreserved PHHs (three donors per compound) for 1, 2 and 7 days. The median of the EC50 values of all compounds decreased 1.78-fold on day 2 compared to day 1, and 1.89-fold on day 7 compared to day 1. Median values of EC50 ratios of all compounds at day 2 and day 7 were close to one but for individual compounds the ratio increased up to almost six. Strong correlations were obtained for EC50 on day 1 and day 7 (R = 0.985; 95% CI 0.960–0.994), day 1 and day 2 (R = 0.964; 95% CI 0.910–0.986), as well as day 2 and day 7 (R = 0.981; 95% CI 0.955–0.992). However, compound specific differences also occurred. Whereas, for example, busulfan showed a relatively strong increase on day 7 compared to day 1, cytotoxicity of acetaminophen did not increase during longer incubation periods. To validate the observed correlations, a publicly available data set, containing data on the cytotoxicity of human hepatocytes cultivated as spheroids for incubation periods of 5 and 14 days, was analyzed. A high correlation coefficient of EC50 values at day 5 and day 14 was obtained (R = 0.894; 95% CI 0.798–0.945). In conclusion, the median cytotoxicity of the test compounds increased between 1 and 2 days of incubation, with no or only a minimal further increase until day 7. It remains to be studied whether the different results obtained for some individual compounds after longer exposure periods would correspond better to human-repeated dose toxicity.

read more

Content maybe subject to copyright    Report

Relevance oftheincubation period incytotoxicity testing withprimary
human hepatocytes
XiaolongGu
1,2
· WiebkeAlbrecht
1
· KarolinaEdlund
1
· FranziskaKappenberg
3
· JörgRahnenführer
3
·
MarcelLeist
4
· WolfgangMoritz
5
· PatricioGodoy
1
· CristinaCadenas
1
· RosemarieMarchan
1
· TimBrecklinghaus
1
·
LaiaTolosaPardo
6
· JoséV.Castell
6
· IainGardner
7
· BoHan
2
· JanG.Hengstler
1
· ReginaStoeber
1
Abstract
Primary human hepatocytes (PHHs) remain the gold standard for invitro testing in the field of pharmacology and toxicol-
ogy. One crucial parameter influencing the results of invitro tests is the incubation period with test compounds. It has been
suggested that longer incubation periods may be critical for the prediction of repeated dose toxicity. However, a study that
systematically analyzes the relationship between incubation period and cytotoxicity in PHHs is not available. To close this
gap, 30 compounds were tested in a concentration-dependent manner for cytotoxicity in cultivated cryopreserved PHHs
(three donors per compound) for 1, 2 and 7days. The median of the EC
50
values of all compounds decreased 1.78-fold on
day 2 compared to day 1, and 1.89-fold on day 7 compared to day 1. Median values of EC
50
ratios of all compounds at day
2 and day 7 were close to one but for individual compounds the ratio increased up to almost six. Strong correlations were
obtained for EC
50
on day 1 and day 7 (R = 0.985; 95% CI 0.960–0.994), day 1 and day 2 (R = 0.964; 95% CI 0.910–0.986), as
well as day 2 and day 7 (R = 0.981; 95% CI 0.955–0.992). However, compound specific differences also occurred. Whereas,
for example, busulfan showed a relatively strong increase on day 7 compared to day 1, cytotoxicity of acetaminophen did
not increase during longer incubation periods. To validate the observed correlations, a publicly available data set, containing
data on the cytotoxicity of human hepatocytes cultivated as spheroids for incubation periods of 5 and 14days, was analyzed.
A high correlation coefficient of EC
50
values at day 5 and day 14 was obtained (R = 0.894; 95% CI 0.798–0.945). In conclu-
sion, the median cytotoxicity of the test compounds increased between 1 and 2days of incubation, with no or only a minimal
further increase until day 7. It remains to be studied whether the different results obtained for some individual compounds
after longer exposure periods would correspond better to human-repeated dose toxicity.
Keywords Hepatotoxicity· Primary human hepatocyte· Incubation period· Cell-titer-blue
Abbreviations
APAP Acetaminophen
ASP Aspirin
BOS Bosentan
BPR Buspirone
Xiaolong Gu and Wiebke Albrecht shared first authorship.
Jan G. Hengstler
hengstler@ifado.de
1
Leibniz Research Centre forWorking Environment
andHuman Factors attheTechnical University ofDortmund
(IfADo), 44139Dortmund, Germany
2
College ofVeterinary Medicine, Yunnan
Agricultural University, Kunming650201, Yunnan,
PeoplesRepublicofChina
3
Department ofStatistics, TU Dortmund University,
44227Dortmund, Germany
4
In Vitro Toxicology andBiomedicine, Department
ofBiology, University ofKonstanz, Universitätsstr. 10, PO
Box M657, 78457Konstanz, Germany
5
InSphero AG, Technoparkstr. 1, 8005Zürich, Switzerland
6
Unit forCell Therapy, University La Fe Hospital, Valencia,
Spain
7
Simcyp, Sheffield, UK
Konstanzer Online-Publikations-System (KOPS)
URL: http://nbn-resolving.de/urn:nbn:de:bsz:352-2-udjshu3svswc0
Erschienen in: Archives of Toxicology ; 92 (2018), 12. - S. 3505-3515
https://dx.doi.org/10.1007/s00204-018-2302-0

3506
BUSF Busulfan
CBZ Carbamazepine
CHL Chlorpheniramine
CLON Clonidine
DFN Diclofenac
DMSO Dimethyl sulfoxide
DILI Drug-induced liver injury
EtOH Ethanol
FAM Famotidine
Glc Glucose
HYZ Hydroxyzine
INAH Isoniazid
KC Ketoconazole
LAB Labetalol
LEV Levofloxacin
MEL Melatonin
MePa Methylparaben
NAC N-Acetylcysteine
NIM Nimesulide
NFT Nitrofurantoin
PhB Phenylbutazone
PMZ Promethazine
PPL Propranolol
RIF Rifampicin
TSN Triclosan
VPA Valproic acid
Vit C Vitamin C
Introduction
Drug-induced liver injury (DILI) is one of the principal
reasons for drug withdrawal from the market (Godoy etal.
2013; Hewitt etal. 2007). DILI also belongs to the most
frequent causes of acute liver failure in industrialized coun-
tries (Bernal etal.
2010; Ostapowicz etal. 2002; Wilke etal.
2007), and occurs despite conducting standard preclinical
tests, such as subchronic and chronic rodent studies.
Currently, primary human hepatocytes represent the gold
standard model for invitro testing of drug metabolism and
cytotoxicity (LeCluyse
2001). For cytotoxicity testing, incu-
bation periods of 1 or 2days are usually used (Arbo etal.
2016; Ghallab etal. 2016); however, it has been reported
that longer incubation periods may influence the test result
(Proctor etal.
2017). A study that systematically analyzes
the relationship between incubation period and cytotoxic-
ity in primary human hepatocytes (PHHs) is not yet avail-
able. Therefore, we selected a set of 30 compounds, mostly
pharmaceutical drugs, to perform concentration and time
dependent incubations of cultivated hepatocytes. The aim of
the present study was to compare cytotoxicity after 1, 2 and
7days of test compound exposure to understand, if EC50
values change depending on the length of the incubation
period, and whether this change is by a similar factor for all
compounds or if large compound specific differences occur.
The relevance of the observed effects for toxicological rou-
tine testing will be discussed.
Materials andmethods
Chemicals andcells
Williams medium E, penicillin/streptomycin solution, Sera-
Plus (FCS), and stable
L
-glutamine were purchased from
PAN Biotech (Aidenbach, Germany), Gentamicin (10mg/
mL) was obtained from Invitrogen Corp. (Karlsruhe, Ger-
many) and insulin supplement (ITS), dexamethasone, trypan
blue solution, and all test compounds except ethanol were
purchased from Sigma-Aldrich (St. Louis, USA). Ethanol
was obtained from VWR chemicals (Mannheim, Germany),
and rat-tail tendon collagen I for monolayer culture was
obtained from Roche (Mannheim, Germany). Cell-Titer-
Blue Cell Viability assay was purchased from Promega
(Mannheim, Germany), and cryopreserved primary human
hepatocytes were obtained from BioreclamationIVT (Balti-
more, USA) (details in Supplement 1).
Cell culture
Cryopreserved primary human hepatocytes (PHH) from
three donors (AFJ, IAN and MSW) (BioreclamationIVT)
were used. Cultivation of cryopreserved hepatocytes was
performed according to a published standard operating pro-
cedure (SOP) (Godoy etal.
2013) with modifications. The
SOP used for the current study is available in Supplement 2.
Briefly, for the gel preparation, a bottle of 10mg lyophilized
rat-tail collagen was dissolved overnight in 40mL 0.2% ace-
tic acid at 4°C. Each well of 96-well plates was coated with
100μL (250μg/mL) collagen solution. The collagen solu-
tion was removed immediately, and the plates were left to
dry overnight under the cell culture hood. The plates coated
with collagen were washed three times with sterile PBS.
Cryopreserved primary human hepatocytes were thawed
in a water bath (37°C) and immediately transferred into
a Falcon tube with culture medium containing 10% FCS.
After cell counting using Trypan blue to determine viability,
50,000 cells in FCS-containing medium were plated into
each well of 96-well plates and kept at 37°C for at least
3h. For homogenous distribution of the cells, the plate was
gently shaken every 5–10min during the first half hour of
incubation. After the attachment period of 3h, the cells were
washed with warm sterile PBS three times, and 200μL FCS
free culture medium was added per well, which was kept at
37°C in the incubator overnight.

3507
Incubation ofprimary human hepatocytes withtest
compounds andcytotoxicity test
The day after plating, the cells were exposed to the con-
centrations of test compounds as indicated in the “
Results
section. If solubility was sufficient, the concentration range
was adjusted to include at least one cytotoxic (below EC
50
)
concentration. For some compounds, the used concentra-
tions were limited by the maximal solubility of the corre-
sponding compound. In case of water soluble compounds,
substances were dissolved in medium and sterile filtered
using 0.22-μm membrane filters before adding to the cells.
For compounds not sufficiently soluble in culture medium,
DMSO was used as a solvent. If sufficient, 0.1% DMSO was
used. Only when the cytotoxic test compound concentrations
were not reached with 0.1% DMSO, the solvent concentra-
tion was increased to 0.5%. The applied DMSO stock solu-
tions for each compound and the tested compound concen-
trations are given in Suppl. Table1A and B. The DMSO
stock solutions were added to the culture medium to obtain
the final test concentrations. The culture medium contains
11mM glucose. Therefore, the indicated concentrations of
glucose were added additionally to this basal glucose con-
centration. For single exposure, the cells were incubated
with compounds for 24h or 48h; for repeated exposure,
the compound-containing medium was renewed every 48h
and the cells were incubated for a total of 7days. The cyto-
toxicity test (Cell-Titer-Blue) was performed according to
an optimized SOP (Supplement 3) and the manufacturer’s
instructions. Briefly, after the cells were incubated with
compounds for the indicated time periods, the compound-
containing medium was removed, cells were washed with
warm sterile PBS three times, and 100μL fresh FCS-free
medium with 20% Cell-Titer-Blue® reagent was added to
each well. After 3h, the supernatant was transferred to black
polystyrene 96-well plates and the fluorescence intensity
was detected with the Tecan Infinite M200 Pro plate reader
using the i-control software. Cells cultivated with culture
medium only or with the solvent DMSO only (0.1% and
0.5% DMSO; Suppl. Table1) were used as a reference for
100% viability. The applied solvent concentrations of 0.1%
or 0.5% DMSO did not cause any cytotoxicity compared to
cells cultivated in medium without DMSO. Cell viability
was calculated after background subtraction and expressed
as percentage of control. PHH of three donors were used as
three biological replicates and for each donor four technical
replicates were analyzed for the fluorescence read out.
Statistical analysis
The raw data were initially processed as follows: background
controls (fluorescence values from Cell-Titre-Blue Reagent®
mixed with medium that was not in contact with cells) were
subtracted from each data point. Replicates of control values
and of exposed samples were averaged (donor wise). Next,
averaged exposed samples were divided by the correspond-
ing averaged control values and multiplied by 100 to obtain
a percentage. Based on the assumption that the response
dependency of the concentration can be described by a sig-
moidal curve, a four-parameter log-logistic model (4pLL)
was fitted to the data. Due to the non-linearity of the 4pLL
model, the function was approximated according to the least
square method with the Gauss–Newton algorithm. Then the
individual values of each concentration were divided by the
value of the left asymptote of the fitted curve. Again, a 4pLL
model was fitted to the data. EC
20
and EC
50
values were
calculated as the concentrations where the sigmoidal curve
attains the values 80 and 50%, respectively. The advantage
of this fitting procedure is that the left asymptote is used
as a control level for calculation of EC
50
and EC
20
values
which are more robust than just using the values of the sol-
vent controls. For calculating confidence intervals of the EC
values, the concept of the ALEC (absolute lowest effective
concentration) was used (Grinberg
2017). EC
20
and EC
50
values were calculated as the concentrations where the sig-
moidal curve attains the values 80% and 50%, respectively.
Confidence intervals of the EC values were calculated using
ALEC (absolute lowest effective concentration) and the delta
method, as described in Grinberg
2017. EC values above
the highest tested concentration, as well as for cases where
the left asymptote lies above 80 or 50%, respectively, were
recorded as “>highest concentration”. The EC values of the
three donors were summarized as follows: the median was
used when all three EC values were smaller than the highest
tested concentration. When two of the three EC values were
below the highest tested concentration, the second lowest
value was used. When only one of the three EC values was
below the highest tested concentration, values of the three
donors were summarized as “>highest concentration”. The
latter values were only included as descriptive measures
into the “
Results” section but were excluded from further
calculations, such as the establishment of the box plots in
Fig.
2c and the correlation analyses in Figs.3 and 4. For the
test compound melatonin, day 1, the value of the first donor
was omitted and the mean of the two other values was used.
Pearson correlation coefficients were calculated between the
logarithmic EC summary values for two incubation times.
An upper and lower threefold deviation line was added to the
correlation plots. The upper deviation lines were obtained
by adding three (log10 scale) to the Y-axis distance of the
regression line. Correspondingly, the lower deviation line
was obtained by subtracting three (log10 scale) from the
Y-axis distance of the regression line. The statistical analy-
ses were performed with the statistical programming lan-
guage R-version 3.1.1. [
https ://www.R-proje ct.org/]. For
fitting concentration–response curves, the R-package drc

3508
(http://journ als.plos.org/ploso ne/artic le?id=10.1371/jour n
al.pone.01460 21
) was used.
Results
Selection oftest compounds andconcentration
ranges
In total, 30 compounds were selected for time- and con-
centration-dependent cytotoxicity testing (Suppl. Table1).
In addition to pharmaceuticals, ethanol, glucose, vitamin C
and DMSO were also tested. For half of the selected com-
pounds an increased risk of hepatotoxicity was previously
reported, whereas no increased risk has been reported for the
further 15 compounds at therapeutic doses (Suppl. Table1).
The tested concentrations and solvents are given in Suppl.
Table1.
Influence oftheincubation period oncytotoxicity
For cytotoxicity testing, cryopreserved hepatocytes from
three donors were used, whose characteristics are sum-
marized in Table
1. Three representative examples of the
cytotoxicity tests are given in Fig.
1, and all results and raw
data are available in the supplement (Suppl. Fig.1; Suppl.
Table2–4). The examples of propranolol (PPL), levofloxa-
cin (LEV) and clonidine (CLON) illustrate a concentration-
dependent increase in cytotoxicity for all three exposure
periods (Fig.
1a–c). In Fig.1, the EC
50
is illustrated. Simi-
larly, the EC
20
values were determined (Suppl. Fig.1).
To summarize the data, bar plots were generated for
median EC
50
values of all compounds (Fig.2a). The fig-
ure illustrates the large, more than 1000-fold, differences in
EC
50
values among the compounds, with ketoconazole and
promethazine representing the most, and dimethyl sulfox-
ide, glucose and ethanol the least cytotoxic compounds for
all tested incubation periods. Next, the ratios of the median
EC
50
values for the different incubation periods were calcu-
lated (Fig.
2b). Acetaminophen is an example of a compound
for which cytotoxicity did not increase after 7 days com-
pared to 1day of incubation (but rather showed a decrease).
In contrast, busulfan shows a relatively strong increase in
cytotoxicity after 7 days compared to 1day of incubation
(Fig.
2b). The median EC
50
ratio of all compounds was high-
est (1.89-fold) for days 1–7 (Fig.
2c). The second highest
median EC
50
ratio (1.78-fold) was obtained for days 1–2.
Median values of EC
50
ratios of all compounds at day 2 and
day 7 did not show a major difference but for many indi-
vidual compounds the ratio was different from one (Fig.
2b).
The complete set of EC
50
and EC
20
values including the
ratios is given in Suppl. Fig.2 and Suppl. Table2.
For statistical evaluation, correlation plots were created
for log
10
EC
50
values with the different incubation periods
on the x- and y-axes. The longer incubation period is shown
on the y-axis (Fig.
3). Data points indicate the experimen-
tally obtained EC
50
values for the 30 compounds, for which
the median of three donors is shown. For some of the less
toxic compounds, viability was not sufficiently reduced to
calculate an EC
50
value, because their limited solubility did
not allow for the testing of higher concentrations. Toxicity
data of compounds that did not reach EC
50
or EC
20
were
not used for further calculations, such as box plot (Fig.
2c)
or correlation analyses (Figs.
3, 4). EC
50
values after 1and
7days of incubation showed a high correlation with a cor-
relation coefficient (R) of 0.985 (with 95% confidence inter-
val [0.960, 0.994]) (Fig.
3a). A high correlation coefficient
means that the relationship between days 1 and 7 is similar
across most compounds. If all compounds would lie on or
very close to the regression line, this would mean that the
EC
50
values of longer incubation periods could be deduced
from the EC
50
values of shorter incubation periods. The
majority of compounds were within a threefold deviation
range from the regression line (plotted as a parallel line on
logarithmic scale); however, the distance of individual com-
pounds from the regression line may differ by more than
fivefold (Fig.
3a). The compounds with the highest day 1/7
ratio are busulfan, famotidine and isoniazid. Similarly good
correlations were obtained for the scatter plots of day 1 ver-
sus day 2 (R = 0.964) (Fig.
3b), as well as day 2 versus day 7
(R = 0.981) (Fig.
3c). The majority of data points were below
the diagonal line, indicating higher levels of cytotoxicity for
the longer incubation period. Similar correlation plots were
obtained for both EC
50
and EC
20
(Fig.4a–c). As observed
Table 1 Characteristics of the hepatocyte donors
Detailed donor characteristics as provided by the commercial source of human hepatocytes (Supplement 1)
CVA cerebral vascular accident
Donor no. and
abbreviation
Sex Age (year) Diagnosis Height (cm) Weight (kg) Medication Alcohol
(Y/N)
Tobacco
(Y/N)
1 (AFJ) M 54 Heart failure 177.8 75 Advil, Prilosec Y Y
2 (IAN) M 48 Head trauma 177.8 70 None Y Y
3 (MSW) M 69 CVA, stroke 179.8 80 None Y Y

3509
for EC
50
, lower values were also obtained for EC
20
, when
longer incubation periods were used. Correlation coefficients
of the EC
20
values (Fig.3) were lower compared to those
of EC
20
(Fig.4) suggesting that just beginning cytotoxicity
(EC
20
) shows larger deviations from the regression line than
half-maximal (EC
50
) cytotoxicity.
Influence oftheincubation period oncytotoxicity
inpublished data
Recently, Proctor etal. (2017) published cytotoxicity data
with different incubation periods. To our knowledge, this
is the only available public data set of human hepatocytes
where cytotoxicity of a larger number of compounds
has been studied with different exposure periods (data
in supplement TableS4 of Proctor etal.
2017). Proctor
etal. incubated spheroids of human hepatocytes for 4
and 14days. However, they did not analyze correlations
between the time points in their study. A correlation analy-
sis was performed in the present study and is illustrated
in Fig.
5. The result shows a highly significant correla-
tion with a correlation coefficient of R = 0.894, which is
similar to the correlation coefficients obtained for our
data. The largest difference between day 14 and day 5 was
obtained for atorvastatin (EC
50
day 14: 0.006mM; EC
50
day 5: 0.0707mM). Surprisingly, for some compounds
lower EC
50
values were obtained for the shorter incubation
period (e.g. flutamide: EC
50
day 14: 0.0257mM; EC
50
day
5: 0.0125mM; and phenformin: EC
50
day 14: 0.0125mM;
EC
50
days 5–6: 0.0077mM).
Fig. 1 Representative examples of Cell-Titer-Blue cytotoxicity data
for propranolol (a), levofloxacin (b), and clonidine (c) in primary
human hepatocytes after incubation for 1, 2 and 7days. The corre-
sponding data for all 30 compounds are available in Suppl. Fig.1 and
Suppl. Table2–4. The concentration-dependent curves represent data
from three donors with four technical replicates each. The cell viabil-
ity for each concentration is presented as the percentage of untreated
controls. Gray symbols indicate the viability values for each technical
replicate normalized to untreated controls; whereas, black symbols
represent the mean values of all technical replicates for each concen-
tration. The vertical line indicates the concentration which causes
50% loss of viability (EC
50
). The dashed vertical line shows the 95%
confidence interval for the concentration. The resulting EC
50
values
are given for each panel. (Color figure online)

Citations
References
More filters
Journal ArticleDOI

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Patricio Godoy, +94 more
TL;DR: This review encompasses the most important advances in liver functions and hepatotoxicity and analyzes which mechanisms can be studied in vitro and how closely hepatoma, stem cell and iPS cell–derived hepatocyte-like-cells resemble real hepatocytes.
Journal ArticleDOI

Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.

TL;DR: Overall, primary cultures of human hepatocytes can serve as a sensitive and selective model for predicting the regulation of CYP450 modulation by drugs and other xenobiotics.
Related Papers (5)

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Patricio Godoy, +94 more

Adverse outcome pathways: opportunities, limitations and open questions.

Marcel Leist, +59 more
Frequently Asked Questions (12)
Q1. What contributions have the authors mentioned in the paper "Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes" ?

However, a study that systematically analyzes the relationship between incubation period and cytotoxicity in PHHs is not available. It remains to be studied whether the different results obtained for some individual compounds after longer exposure periods would correspond better to human-repeated dose toxicity. In conclusion, the median cytotoxicity of the test compounds increased between 1 and 2 days of incubation, with no or only a minimal further increase until day 7. 

Therefore, 2 days may represent an adequate choice for cytotoxicity tests with human hepatocytes in future studies, offering the practical advantage that less culture medium changes are required. However, these results should be interpreted with caution and further reproduction is required before possible biological explanations are discussed. 

Due to the non-linearity of the 4pLL model, the function was approximated according to the least square method with the Gauss–Newton algorithm. 

After cell counting using Trypan blue to determine viability, 50,000 cells in FCS-containing medium were plated into each well of 96-well plates and kept at 37 °C for at least 3 h. 

For single exposure, the cells were incubated with compounds for 24 h or 48 h; for repeated exposure, the compound-containing medium was renewed every 48 h and the cells were incubated for a total of 7 days. 

washout experiments with an initial exposure period with test compounds followed by test compound-free incubation or repeated exposure and washout periods may be considered. 

The advantage of this fitting procedure is that the left asymptote is used as a control level for calculation of EC50 and EC20 values which are more robust than just using the values of the solvent controls. 

Only when the cytotoxic test compound concentrations were not reached with 0.1% DMSO, the solvent concentration was increased to 0.5%. 

Compounds with a relatively strong decrease in EC50 after 7 days compared to 1 day are busulfan, famotidine, and isoniazid (Fig. 2b). 

The applied solvent concentrations of 0.1% or 0.5% DMSO did not cause any cytotoxicity compared to cells cultivated in medium without DMSO. 

Dimethyl sulfoxide DILI Drug-induced liver injury EtOH Ethanol FAM Famotidine Glc Glucose HYZ Hydroxyzine INAH Isoniazid KC Ketoconazole LAB Labetalol LEV Levofloxacin MEL Melatonin MePa Methylparaben NAC N-Acetylcysteine NIM Nimesulide NFT Nitrofurantoin PhB Phenylbutazone PMZ Promethazine PPL Propranolol RIF Rifampicin TSN Triclosan VPA Valproic acid Vit C Vitamin CDrug-induced liver injury (DILI) is one of the principal reasons for drug withdrawal from the market (Godoy et al. 2013; Hewitt et al. 2007). 

large efforts are undertaken to establish in vitro tests with the long-term goal to predict human toxicity (Daneshian et al.